Drug Development Pharma - May 13, 2014
Kancera applies for new patent
The company has registered a patent application for new substances for cancer treatment that selectively inhibit the enzyme HDAC6. The new patent application is based on HDAC6 inhibitors ability to affect mechanisms both inside of and outside of the cell nucleus. According to an announcement from the company it has been proven that HDAC6 has […]
Drug Development Pharma - May 8, 2014
SARomics enters alliance with Swiss firm
SARomics Biostructures has entered into a strategic drug discovery partnership with inSili.com. The two companies are to perform collaborative research with the goal of finding novel bioactive agents against therapeutic drug targets. The focus of the collaboration aims at identifying new lead- and drug-like molecular entities with innovative modes of action, and obtaining structures of […]
Drug Development Pharma - April 9, 2014
EMA introduces new fee incentives for SMEs
The European Medicines Agency has introduced new fee incentives to support micro, small and medium-sized enterprises (SMEs) developing medicines for human and veterinary use.
Drug Development Pharma - April 4, 2014
Diamyd to open cord blood bank
The company will invest SEK 11.5 million for the establishment of a commercial cord blood bank in Sweden for private family saving of umbilical cord blood and other sources of stem cells.
Drug Development Pharma - April 1, 2014
FDA approves Sobi’s Alprolix
Sobi’s partner Biogen Idec have announced that the US Food and Drug Administration (FDA) has approved Alprolix.
Drug Development Pharma - March 25, 2014
Russian yes to simeprevir
The Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, announces Medivir. Russia will be the first country within EMEA to gain access to simeprevir. “The Russian approval is another important event for simeprevir and provides the hepatitis C patients in Russia with a new HCV treatment” […]
